Handelsbanken Fonder AB Acquires 21,990 Shares of Zoetis Inc. $ZTS

Handelsbanken Fonder AB boosted its holdings in Zoetis Inc. (NYSE:ZTS) by 10.7% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 228,467 shares of the company’s stock after purchasing an additional 21,990 shares during the quarter. Handelsbanken Fonder AB’s holdings in Zoetis were worth $16,418,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. RFG Advisory LLC grew its holdings in Zoetis by 4.9% during the 4th quarter. RFG Advisory LLC now owns 1,708 shares of the company’s stock valued at $215,000 after buying an additional 80 shares in the last quarter. Quest 10 Wealth Builders Inc. increased its position in Zoetis by 4.7% during the fourth quarter. Quest 10 Wealth Builders Inc. now owns 1,904 shares of the company’s stock valued at $240,000 after acquiring an additional 86 shares during the last quarter. Financial Engines Advisors L.L.C. grew its holdings in Zoetis by 4.4% during the 3rd quarter. Financial Engines Advisors L.L.C. now owns 2,043 shares of the company’s stock valued at $299,000 after purchasing an additional 87 shares during the last quarter. Generali Investments Towarzystwo Funduszy Inwestycyjnych grew its stake in shares of Zoetis by 20.9% during the fourth quarter. Generali Investments Towarzystwo Funduszy Inwestycyjnych now owns 520 shares of the company’s stock valued at $65,000 after buying an additional 90 shares during the last quarter. Finally, Physician Wealth Advisors Inc. increased its stake in Zoetis by 17.4% in the first quarter. Physician Wealth Advisors Inc. now owns 615 shares of the company’s stock worth $73,000 after purchasing an additional 91 shares during the period. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Zoetis Trading Down 2.5%

Zoetis stock opened at $73.47 on Thursday. The stock has a 50-day moving average price of $76.49 and a 200 day moving average price of $99.53. The company has a market capitalization of $30.36 billion, a price-to-earnings ratio of 12.10, a price-to-earnings-growth ratio of 1.30 and a beta of 0.74. Zoetis Inc. has a 52 week low of $71.45 and a 52 week high of $160.48. The company has a quick ratio of 1.84, a current ratio of 3.08 and a debt-to-equity ratio of 2.87.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Thursday, August 6th. The company reported $1.87 earnings per share for the quarter, topping the consensus estimate of $1.85 by $0.02. Zoetis had a net margin of 27.49% and a return on equity of 74.89%. The company had revenue of $2.47 billion for the quarter, compared to the consensus estimate of $2.50 billion. During the same quarter in the prior year, the company earned $1.76 EPS. Zoetis’s quarterly revenue was down .2% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. Sell-side analysts anticipate that Zoetis Inc. will post 6.19 EPS for the current year.

Zoetis Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Monday, July 20th will be paid a $0.53 dividend. The ex-dividend date is Monday, July 20th. This represents a $2.12 dividend on an annualized basis and a dividend yield of 2.9%. Zoetis’s dividend payout ratio is presently 34.93%.

Analysts Set New Price Targets

ZTS has been the topic of a number of research reports. BNP Paribas Exane reduced their target price on shares of Zoetis from $146.00 to $110.00 and set an “outperform” rating on the stock in a research report on Tuesday. TD Cowen reduced their target price on shares of Zoetis from $150.00 to $104.00 and set a “buy” rating for the company in a report on Tuesday, June 30th. Citigroup decreased their price objective on Zoetis from $112.00 to $96.00 and set a “buy” rating for the company in a report on Tuesday. HSBC decreased their price objective on shares of Zoetis from $140.00 to $95.00 and set a “buy” rating for the company in a research report on Monday, July 6th. Finally, Stifel Nicolaus cut their target price on Zoetis from $95.00 to $85.00 and set a “hold” rating on the stock in a research report on Friday, June 26th. Eight research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $109.62.

Zoetis News Roundup

Here are the key news stories impacting Zoetis this week:

• Positive Sentiment: Citigroup maintained a “buy” rating despite lowering its price target from $112 to $96, while BNP Paribas Exane maintained an “outperform” rating and reduced its target from $146 to $110. Both targets imply substantial upside from current levels. Citigroup and BNP Paribas Exane price target updates
• Positive Sentiment: Recent analyst coverage remains mixed rather than uniformly bearish: HSBC issued a “buy” rating, and the median price target from seven analysts is $99. Zoetis also reported quarterly earnings slightly above consensus and has recently attracted purchases from some institutional investors and company insiders.
• Neutral Sentiment: The broader analyst consensus is “hold,” reflecting uncertainty over the pace of recovery. Zacks Research separately downgraded the stock from “hold” to “strong sell,” highlighting the increasingly divided view on Zoetis’ near-term prospects. Zacks Research rating update
• Negative Sentiment: Investors remain concerned about softer U.S. companion-animal demand, including fewer veterinary visits, greater price sensitivity among pet owners and heavier competition in dermatology and parasiticides. These pressures have affected key brands and contributed to weaker sales trends. Zoetis pet-care demand and competitive pressure analysis
• Negative Sentiment: Zoetis reduced its 2026 revenue-growth and adjusted-earnings outlook in May. The market is still digesting the lower expectations, while recent target cuts from Piper Sandler, Citigroup and BNP Paribas Exane have reinforced concerns that a recovery may take longer than expected. Piper Sandler forecast for Zoetis
• Negative Sentiment: The stock recently reached a new 52-week low after an analyst downgrade, intensifying technical and sentiment pressure. Although quarterly EPS exceeded estimates, revenue fell slightly year over year and missed consensus, limiting the positive impact of the earnings beat. Zoetis 52-week low report

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.